As the pharmaceutical industry develops increasingly expensive medicines – notably, those costing seven figures – a new survey finds the largest employers in the U.S. plan to boost the use of various tactics to mitigate the expense and, in some cases, possibly postpone access for employees.

For instance, 44% of 122 employers expect to delay placing million-dollar-drugs on their formularies for a set amount of time, or at least until a pharmacy benefits manager vets safety and effectiveness. Although this is not a new tactic, that’s up from 26% last year, according to the survey by the Business Group on Health, a non-profit that represents employers on health policy and workforce matters.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy